Scored Bilayer Tablet Composition for Stable HIV Drug Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of tenofovir disoproxil fumarate, emtricitabine, and efavirenz face stability issues, incompatibilities, increased tablet size, swallowing difficulties, and reduced dissolution rates due to high binder and lubricant usage, necessitating a stable, compliant, and high-dissolution bilayer tablet form.
Innovation Solution
A bilayer tablet composition with discrete layers of tenofovir disoproxil fumarate and emtricitabine, and efavirenz, utilizing hydroxypropyl cellulose, low amounts of binders and lubricants, and sodium lauryl sulfate to enhance stability, dissolution, and hardness, with a film coating for moisture protection and scored design for easier administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a single dosage form comprising all three compounds (tenofovir, emtricitabine, and efavirenz) is formulated, then patient compliance is improved, but tablet size increases causing swallowing difficulty
Solution Approach 1:
The patent divides the single tablet into two separate layers: first layer containing tenofovir disoproxil fumarate and emtricitabine, second layer containing efavirenz. This segmentation allows each layer to be optimized independently for size and composition, reducing overall tablet volume while maintaining all three active ingredients in a single dosage form for improved patient compliance
Solution Approach 2:
The patent transitions from a single-layer homogeneous structure to a bilayer heterogeneous structure, adding the dimension of layering. This allows the tablet to maintain a compact size by organizing components vertically in distinct layers rather than mixing them uniformly, thereby reducing swallowing difficulty while preserving compliance benefits
2Stability of the object's composition
If high amounts of binder and lubricant are used to ensure chemical stability, then stability is improved, but dissolution rate decreases
Solution Approach 1:
The patent applies different binder and lubricant formulations to different layers. The first layer uses binders such as microcrystalline cellulose and lubricants such as magnesium stearate at optimized concentrations, while the second layer uses different binders such as pregelatinized starch and lubricants such as calcium stearate. This local optimization ensures chemical stability in each layer while minimizing the negative impact on dissolution rate through controlled excipient selection and placement
Solution Approach 2:
The patent optimizes the concentration parameters of binders and lubricants to minimal effective amounts rather than high amounts. By changing the parameter of excipient concentration from high to low levels, the patent maintains chemical stability through precise formulation control while improving dissolution rate by reducing the barrier effect of excessive excipients
3Stability of the object's composition
If multiple layers are added to ensure stability of each compound, then chemical stability is improved, but tablet complexity increases leading to manufacturing difficulty
Solution Approach 1:
The patent extracts incompatible compounds into separate layers, specifically placing tenofovir disoproxil fumarate and emtricitabine in the first layer and efavirenz in the second layer. This separation eliminates incompatibility issues between the compounds while maintaining a simple bilayer structure that is easier to manufacture than a complex multilayer system, as it requires only one interface rather than multiple interfaces
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bilayer tablet achieves high stability, compliance, improved dissolution rates, reduced friability, and increased crushing strength, addressing swallowing difficulties and ensuring effective drug delivery.
Implementation Method 1
hydroxypropyl cellulose, low amounts of binders and lubricants
Implementation Method 2
sodium lauryl sulfate to enhance stability, dissolution, and hardness
Implementation Method 3
with a film coating for moisture protection
Data Source
Figure 1~3
Figure 4~5
AI summary
The present invention relates to a scored bilayer tablet comprising tenofovir or a pharmaceutically acceptable salt thereof, emtricitabine or a pharmaceutically acceptable salt thereof and efavirenz or a pharmaceutically acceptable salt thereof.